A pharmacovigilance study on FDA approved interleukin inhibitor-associated alopecia in the treatment of psoriasis
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
المؤلف الرئيسي: | Islam, Nahidul |
---|---|
مؤلفون آخرون: | Talukder, Mesbah |
التنسيق: | أطروحة |
اللغة: | English |
منشور في: |
Brac University
2023
|
الموضوعات: | |
الوصول للمادة أونلاين: | http://hdl.handle.net/10361/22025 |
مواد مشابهة
-
TNF-α inhibitor-induced alopecia in psoriatic disease patients: a pharmacovigilance study
بواسطة: Afroza, Halima
منشور في: (2024) -
Biologics and Biosimilars as Treatment Options for Psoriasis
بواسطة: Moya, Amena Khatun
منشور في: (2023) -
Association of GLP-1 receptor agonists and risk of pancreatitis: a pharmacovigilance study based on FAERS database
بواسطة: Bishakha, Adwiza Chakraborty
منشور في: (2024) -
Safety and efficacy of dutasteride for male Androgenetic Alopecia
بواسطة: Islam, S.M. Zahidul
منشور في: (2024) -
Relationship between SGLT2 inhibitor use and risk of lower limb amputations: a pharmacovigilance study
بواسطة: Khandker, Tahia Anjum
منشور في: (2024)